Clinical Study
Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
Table 3
Adverse events of everolimus (EVL) during 12 months of Follow-up1.
| Adverse event | 1.0 mg of EVL () | 1.5 mg of EVL () | P value |
| Patients who discontinued everolimus treatment before 12 months | | | | Death | 0 | 2 (3.6) | 0.272 | Graft loss | 0 | 0 | >0.999 | Lost to follow-up | 0 | 0 | >0.999 | Adverse events leading to EVL discontinuation | 12 (23.5) | 19 (33.9) | 0.166 | Infection | 6 (11.8) | 1 (1.8) | 0.043 | Edema and/or dyspnoe(total) | 5 (7.8) | 10 (17.9) | 0.105 | Lingual edema | 0 | 1 (1.8) | 0.523 | Diarrhea | 0 | 1 (1.8) | 0.523 | Epitaxis | 1 (2.0) | 2 (3.6) | 0.523 | Cytopenia | 0 | 4 (7.1) | 0.048 | Urticaria | 0 | 1 (1.8) | 0.523 | All patients | 22 (43.1) | 35 (62.5) | 0.054 | Rejection | 5 (9.8) | 3 (5.4) | 0.307 | All adverse events | | | | Infection | 10 (19.6) | 2 (3.6) | 0.009 | Edema and/or dyspnoe (total) | 6 (11.8) | 19 (33.9) | 0.011 | Lingual edema | 0 | 2 (3.6) | 0.225 | Diarrhea | 0 | 3 (5.4) | 0.105 | Epitaxis | 1 (2.0) | 0 | 0.523 | Cytopenia | 0 | 5 (8.9) | 0.022 | Urticaria | 0 | 1 (1.8) | 0.523 |
|
|
1Data are presented as numbers and percentages.
|